Roche Diagnostics to sell 454's sequencers:
This article was originally published in Clinica
Executive Summary
Roche Diagnostics' Applied Science unit is to distribute a genome sequencer made by CuraGen subsidiary 454 Life Sciences under a new, five-year, exclusive agreement. 454 Life Sciences, which says its system is up to 100 times faster than other commercially available sequencers, stands to receive up to $62m in licence fees, milestones, minimum royalties and research funding from Roche. Roche has an option to extend its distribution rights to cover the regulated diagnostics market.